echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Migraine medicine! Ajovy automatic syringe of Tyva CGRP antibody drug has been approved by FDA of the United States!

    Migraine medicine! Ajovy automatic syringe of Tyva CGRP antibody drug has been approved by FDA of the United States!

    • Last Update: 2020-01-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    January 29, 2020 / BIOON / -- Teva, an Israeli pharmaceutical giant, recently announced that the US Food and Drug Administration (FDA) has approved the automatic syringe of ajovy (fremanezumab), a migraine drug

    The company has plans to bring the product to market in the coming months

    Brendan O'Grady, executive vice president of Tyva North America business, said: "the approval of ajovy syringes is another important step forward for Tyva and the migraine community

    Ajovy is the only FDA approved anti CGRP migraine therapy that offers a quarterly (675 mg) or monthly (225 mg) dose selection flexibility, and we are pleased that this approved automatic syringe will enable the migraine patient population and their healthcare providers to decide whether the automatic syringe is the right treatment option to meet their needs

    " Migraine is the third most common disease and the sixth general disability disease in the world

    It is a common chronic neurovascular disease, characterized by recurrent severe headache, mostly laterally

    It is estimated that the total number of migraine patients in the world is more than 1 billion, about 90% of them are episodic migraine (EM), which is characterized by 14 days of migraine per month; the remaining 10% are chronic migraine (CM), which is characterized by at least 15 days of headache per month, of which 8 days and more are migraine, and the patient's condition lasts for more than 3 months

    At present, there is no medicine to cure migraine

    The World Health Organization (who) has listed migraine as one of the top 10 most disabling diseases

    Compared with other people, migraine patients are more likely to have depression, anxiety, sleep disorders, other pain and fatigue

    Ajovy is a kind of monoclonal antibody drug, which can target and block the binding of CGRP and its receptor

    CGRP, a neuropeptide, has been shown to be released during migraine attacks and is believed to be an inducement to migraine attacks

    At present, CGRP and its receptor have become the hot target of migraine drug development

    Up to now, three McAb migraine prophylactic drugs targeting CGRP or its receptor have been listed, respectively: Novartis / Amgen aimovig (erenumab), emgality (galcanezumab), and ajovy (fremanezumab)

    In terms of medication, aimovig and emgality are injected subcutaneously once a month, ajovy can be injected subcutaneously once a month or once every three months, which is more convenient in terms of medication and will provide patients with a differentiated treatment option

    In addition to the three antibody drugs mentioned above, the single antibody drug eptinezumab (intravenous infusion once every three months) of alder company has been reviewed in the United States and is expected to be approved in early 2020, with a high response rate of 100% in some patients

    In September 2019, Lingbei acquired alder with USD 1.95 billion

    It is worth mentioning that Lilly emgality was also approved by the US FDA in June 2019 as a new indication for the treatment of adult onset cluster migraine (ECH)

    This approval makes emgality the first and only drug to treat ECH

    It is also the first and only CGRP targeted antibody approved by FDA to treat two different headache diseases

    For TIWA, based on the analysis of ineffectiveness, the company announced in April 2019 to terminate the phase III clinical project of ajov in the treatment of cluster headache

    At present, some companies are developing oral CGRP inhibitors

    In December 2019, ubrogepant was approved by FDA for acute treatment of adult migraine (with or without aura)

    It is worth mentioning that ubralvy is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by FDA for the treatment of migraine attack

    In addition to ubralvy, Aerjian also has an oral CGRP receptor antagonist, atogepant, which has been developed to prevent migraine

    In addition, biohaven also has an oral CGRP receptor antagonist zydis (rimegepant orally disintegrating tablet), which is under review by the US FDA and is expected to be approved in early 2020

    In terms of acute treatment of migraine, in mid October 2019, leyvow (lashiditan) was approved by the US FDA for acute treatment of adult migraine (with or without aura symptoms)

    The approval is significant because reyvow represents the first new class of acute migraine drugs approved by FDA in more than 20 years

    It should be noted that reyvow is not suitable for the prophylactic treatment of migraine

    The dosage specifications of the drug are 50mg, 100mg and 200mg, which can be selected according to the needs

    The active component of reyvow is lasmiditan, which is an oral, central nervous system permeable, selective, 5-hydroxytryptamine 1F (5-HT1F) agonist

    It is different from the currently approved migraine drug in structure and mechanism, and has no vasoconstrictive activity

    It is worth mentioning that lasmiditan is the first and only drug molecule approved for acute treatment of migraine in adults

    This approval represents the first major innovation in the treatment of acute migraine in more than 20 years

    Original source: Teva announcements FDA approval of ajovy (fremanezumab vfrm) injection autoinjector
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.